Updated on Jul 15, 2026, 04:03 AM UTC
|
| ||||
|
| ||||
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cipla | 1,446.85 | 0.58 | 1,16,883.10 | 22.95 | 3.87 | 0.87 | 0.81 |
| Torrent Pharmaceuticals | 4,951.75 | -0.39 | 1,67,642.00 | 67.32 | 17.1 | 0.83 | 17.62 |
| Dr Reddy's Laboratories | 1,238.00 | -0.62 | 1,03,328.03 | 18.63 | 3.14 | 0.63 | 2.34 |
| Sun Pharmaceutical Industries | 1,945.80 | 0.29 | 4,66,851.60 | 36.24 | 5.77 | 0.92 | 0.50 |
| Divi's Laboratories | 7,310.30 | 1.74 | 1,94,065.49 | 78.61 | 11.52 | 0.46 | 0.01 |
| Meeting Date | Purpose |
|---|---|
| 2026-05-12 | Audited Results |
| 2026-02-12 | Quarterly Results |
| 2025-11-12 | Quarterly Results |
| 2025-05-28 | Audited Results |
| 2025-02-12 | Quarterly Results |
Cohance Lifesciences is trading at 438.20 as on Wed Jul 15 2026 04:02:22. This is -0.62% lower as compared to its previous closing price of 440.95.
The market capitalization of Cohance Lifesciences is 16764.09 Cr as on Wed Jul 15 2026 04:02:22.
The average broker rating on Cohance Lifesciences is Hold. The breakup of analyst rating is given below -
The 52 wk high for Cohance Lifesciences is 1121.15 whereas the 52 wk low is 267.85
Cohance Lifesciences can be analyzed on the following key metrics -
Cohance Lifesciences reported a net profit of 179.23 Cr in 2026.
The Mutual Fund Shareholding was 18.57% at the end of 31 Mar 2026.
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.